PA8806901A1 - SOLID FUNCTIONED POLYMER NANOPARTICLES THAT INCLUDE EPOTILONES - Google Patents

SOLID FUNCTIONED POLYMER NANOPARTICLES THAT INCLUDE EPOTILONES

Info

Publication number
PA8806901A1
PA8806901A1 PA20088806901A PA8806901A PA8806901A1 PA 8806901 A1 PA8806901 A1 PA 8806901A1 PA 20088806901 A PA20088806901 A PA 20088806901A PA 8806901 A PA8806901 A PA 8806901A PA 8806901 A1 PA8806901 A1 PA 8806901A1
Authority
PA
Panama
Prior art keywords
substances
epotilones
functioned
solid
polymer nanoparticles
Prior art date
Application number
PA20088806901A
Other languages
Spanish (es)
Inventor
Katrin Fisher
Sascha General
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PA8806901A1 publication Critical patent/PA8806901A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCRIBEN NANOPARTÍCULAS POLIMÉRICAS CON POTENCIAL SUPERFICIAL CATIÓNICO EN LAS CUALES PUEDEN ENCAPSULARSE SUSTANCIAS NEUTRAS, HIDROFÓBICAS E HIDROFÍLICAS CON ACTIVIDAD FARMACÉUTICA. LAS SUSTANCIAS HIDROFÍLICAS, Y POR LO TANTO, SOLUBLES EN AGUA, SE ENCAPSULAN EN LA PARTÍCULA QUE CONSTITUYE EL NÚCLEO POR CO-PRECIPITACIÓN, MEDIANTE LA COMPLEJIZACIÓN IÓNICA CON UN POLÍMERO CARGADO. COMO SUSTANCIAS CON ACTIVIDAD FARMACÉUTICA PARA LA ENCAPSULACIÓN PUEDEN USARSE AGENTES TERAPÉUTICA Y AGENTES DE DIAGNÓSTICO. LA SUPERFICIE CATIÓNICA DE LA PARTÍCULA PERMITE REALIZAR UNA MODIFICACIÓN ELECTROSTÁTICA ESTABLE DE LA SUPERFICIE CON COMPUESTOS CON CARGAS PARCIALMENTE OPUESTAS, LOS CUALES PUEDEN CONTENER LIGANDOS CON ESPECIFICIDAD POR EL BLANCO PARA MEJORAR EL DIRECCIONAMIENTO PASIVO Y ACTIVO.POLYMERIC NANOPARTICLES WITH CATIONIC SURFACE POTENTIAL ARE DESCRIBED IN WHICH NEUTRAL, HYDROPHOBIC AND HYDROPHYTIC SUBSTANCES WITH PHARMACEUTICAL ACTIVITY CAN BE ENCLOSED. THE HYDROPHYLIC SUBSTANCES, AND THEREFORE, SOLUBLE IN WATER, ARE ENCAPSULATED IN THE PARTICLE THAT CONSTITUTES THE CORE BY CO-PRECIPITATION, THROUGH IONIC COMPLEXIZATION WITH A LOADED POLYMER. AS SUBSTANCES WITH PHARMACEUTICAL ACTIVITY FOR ENCAPSULATION THERAPEUTIC AGENTS AND DIAGNOSTIC AGENTS CAN BE USED. THE CATIÓNICA SURFACE OF THE PARTICLE ALLOWS TO PERFORM A STABLE ELECTROSTATIC MODIFICATION OF THE SURFACE WITH COMPOUNDS WITH PARTIALLY OPPOSED CHARGES, WHICH MAY CONTAIN SPECIFICITY LINKS BY THE WHITE TO IMPROVE THE PASSIVE AND ACTIVE ADDRESS.

PA20088806901A 2007-12-10 2008-12-09 SOLID FUNCTIONED POLYMER NANOPARTICLES THAT INCLUDE EPOTILONES PA8806901A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007059752A DE102007059752A1 (en) 2007-12-10 2007-12-10 Functionalized solid polymer nanoparticles containing epothilones

Publications (1)

Publication Number Publication Date
PA8806901A1 true PA8806901A1 (en) 2009-07-23

Family

ID=40409013

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088806901A PA8806901A1 (en) 2007-12-10 2008-12-09 SOLID FUNCTIONED POLYMER NANOPARTICLES THAT INCLUDE EPOTILONES

Country Status (7)

Country Link
AR (1) AR069638A1 (en)
DE (1) DE102007059752A1 (en)
PA (1) PA8806901A1 (en)
PE (1) PE20091107A1 (en)
TW (1) TW200932220A (en)
UY (1) UY31521A1 (en)
WO (1) WO2009074274A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005725A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
JP2012501965A (en) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド Drug-loaded polymer nanoparticles and methods for producing and using the same
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
WO2010075072A2 (en) 2008-12-15 2010-07-01 Bind Biosciences Long circulating nanoparticles for sustained release of therapeutic agents
CN102361636A (en) * 2009-03-03 2012-02-22 公立大学法人横浜市立大学 Amino acid-conjugated cyanoacrylate polymer particles
EP2509634B1 (en) 2009-12-11 2019-03-06 Pfizer Inc Stable formulations for lyophilizing therapeutic particles
EA201290498A1 (en) * 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. THERAPEUTIC POLYMER NANOPARTICLES, INCLUDING EPOTILON, AND METHODS FOR THEIR PREPARATION AND APPLICATION
JP5965844B2 (en) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド Therapeutic polymer nanoparticle compositions having high glass transition temperature or high molecular weight copolymers
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US9610367B2 (en) 2010-08-24 2017-04-04 Canon Kabushiki Kaisha Particle and contrast agent having the particle
ES2732377T3 (en) 2012-09-17 2019-11-22 Pfizer Therapeutic nanoparticle preparation procedure
JP6564369B2 (en) 2013-12-09 2019-08-21 デュレクト コーポレイション Pharmaceutically active agent conjugates, polymer conjugates, and compositions and methods involving them
BR112016021130A2 (en) 2014-03-14 2017-08-15 Pfizer THERAPEUTIC NANOPARTICLES, PHARMACEUTICAL COMPOSITION INCLUDING THE SAID NANOPARTICLES, PROCESS FOR THE PREPARATION AND USE THEREOF
WO2015181346A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
DE102017100317A1 (en) 2017-01-10 2018-07-12 Friedrich-Schiller-Universität Jena Nanostructured carrier system for gene delivery
WO2024041984A1 (en) * 2022-08-22 2024-02-29 Agfa-Gevaert Nv Near infrared and red light absorbing composite resin particles

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US252028A (en) 1882-01-10 Alonzo s
US262030A (en) 1882-08-01 Wash-stand
US258286A (en) 1882-05-23 Fruit-drier
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
CA2032169A1 (en) * 1989-05-04 1990-11-05 Steven Kornguth Method for localization and treatment of tumors and complexes therefor
US5366860A (en) 1989-09-29 1994-11-22 Applied Biosystems, Inc. Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
DE4138042C2 (en) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilones, their production processes and agents containing these compounds
FR2684103B1 (en) 1991-11-22 1994-09-02 Centre Nat Rech Scient NOVEL COMPOUNDS WITH GUANIDIC STRUCTURE AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
DE4445065A1 (en) 1994-12-07 1996-06-13 Diagnostikforschung Inst Methods for in-vivo diagnostics using NIR radiation
WO1997019086A1 (en) 1995-11-17 1997-05-29 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone derivatives, preparation and use
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19728914A1 (en) 1997-07-07 1999-01-14 Basf Ag Metallic colored polyamides
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
AU9340998A (en) 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
AU9799198A (en) * 1997-10-09 1999-05-03 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
FR2775187B1 (en) 1998-02-25 2003-02-21 Novartis Ag USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT
DE19820599A1 (en) 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh New epothilone derivatives useful as pharmaceuticals and in plant protection
WO1999067253A2 (en) 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
SE517641C2 (en) 1998-07-02 2002-07-02 Sca Hygiene Prod Ab Process for making a material layer with barrier tabs and a surface layer with such barrier tabs
JP2000095758A (en) 1998-09-18 2000-04-04 Schering Ag Near-infrared, fluorescent contrast medium, and its production
ATE248175T1 (en) 1998-12-22 2003-09-15 Novartis Pharma Gmbh EPOTHILONE DERIVATIVES AND THEIR USE AS ANTI-TUMOR AGENTS
DE19908760A1 (en) 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
DE19908763A1 (en) 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable benzo-fused epothilon derivatives, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
IL144519A0 (en) 1999-02-18 2002-05-23 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
DE19907588A1 (en) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh New C-21 modified epothilone derivatives useful for treating e.g. cancer and other proliferative diseases and inhibiting angiogenesis and inducing apoptosis
CA2368658A1 (en) 1999-03-29 2000-10-05 Soong-Hoon Kim A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
PE20010116A1 (en) 1999-04-30 2001-02-15 Schering Ag 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTILONE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION
AU7662600A (en) 1999-10-08 2001-04-23 Novartis Ag 13-alkyl epothilone derivatives
WO2001064650A2 (en) 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Center Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
DE10020517A1 (en) 2000-04-19 2001-10-25 Schering Ag New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
US20020045609A1 (en) 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
WO2002008440A2 (en) 2000-07-25 2002-01-31 Kosan Biosciences, Inc. Fermentation process for epothilones
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
US6989450B2 (en) 2000-10-13 2006-01-24 The University Of Mississippi Synthesis of epothilones and related analogs
DE50111753D1 (en) 2000-10-16 2007-02-08 R & D Biopharmaceuticals EPOTHILON SYNTHETIC COMPONENTS I: UNSYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOOD DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE FOR THE PREPARATION OF EPOTHILONES AND EPOTHILONE DERIVATIVES
AU2002338336A1 (en) 2001-04-03 2002-10-21 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
DE102005041860A1 (en) * 2005-09-02 2007-03-08 Schering Ag Nano-particle embedded- and charged-complex, useful for the production of a pharmaceutical composition, comprises two complex partners, where the complex partner is an embedded anionic and a cationic active substance
US20100196280A1 (en) * 2006-06-08 2010-08-05 Katrin Claudia Fischer Functionalized solid polymer nanoparticles for diagnostic and therapeutic applications

Also Published As

Publication number Publication date
UY31521A1 (en) 2009-08-03
TW200932220A (en) 2009-08-01
WO2009074274A1 (en) 2009-06-18
PE20091107A1 (en) 2009-08-29
AR069638A1 (en) 2010-02-10
DE102007059752A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
PA8806901A1 (en) SOLID FUNCTIONED POLYMER NANOPARTICLES THAT INCLUDE EPOTILONES
CR20150523A (en) USE OF 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED KINAZOLINS
CR20140365A (en) CARBAMATE COMPOUNDS AND PREPARATION AND USE OF THE SAME
WO2009029958A3 (en) Implantable delivery device
TR201902125T4 (en) PARASITIDAL ORAL VETERINARY COMPOSITIONS CONTAINING SYSTEMICALLY ACTIVE AGENTS, THEIR METHODS AND USES
CL2008000442A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A CHITOSAN, A COSMETIC OR PHARMACEUTICAL ACTIVE INGREDIENT, AND A VOLATILE SOLVENT; AND ITS USE TO TREAT PSORIASIS, MICOSIS BETWEEN OTHER DISEASES.
BRPI0810899A2 (en) FORMULATION OF ACTIVATED PLGA NANOParticles loaded with ACTIVE AGENT FOR DIRECTIONAL ANTICANETIC NANO-THERAPEUTIC SUBSTANCES.
BRPI0818673A2 (en) combination therapy of an anti-cd20 type ii antibody with an anti-bcl-2 active agent
SV2008003071A (en) PHARMACEUTICAL COMPOSITIONS OF ANTI-CD40 ANTIGONISTS
HN2010002774A (en) DERIVATIVES OF 2- (1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL / 2-OXOIMIDAZOLIDIN-1-IL) PIRIDIN-4-CARBOXAMIDE ACTIVE AS ESTEAROIL-CoA MODULATORS
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
EA201492290A1 (en) COMPOSITIONS AND METHODS FOR VAGINAL DELIVERY OF ANTIPROGHESTINES
BRPI0518869A2 (en) cytotoxic agents comprising taxanes
CR20140334A (en) DIVISIBLE GALENIC FORM THAT ALLOWS A MODIFIED RELEASE OF THE ACTIVE PRINCIPLE
UY31079A1 (en) PHENYLAMINOBENCENE DERIVATIVES SUBSTITUTED FOR USE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH EXTRACELLULAR KINASE ACTIVITY MEDITATED BY MYTHOGENS
UY29086A1 (en) NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS.
CL2011003065A1 (en) Vesicular formulation comprising one or more phospholipids and one or more non-ionic surfactants, free of any pharmaceutically active agent, useful for the treatment of pain associated with osteoarthritis.
DK2281576T3 (en) Active targeting polymer micelle with encapsulated drug and medical composition
PA8796001A1 (en) HISTAMINE H4-FURO-PYRIMIDINE MODULATORS OF THE H4 HISTAMINE RECEIVER
UY29250A1 (en) CYTOTOXIC AGENTS UNDERSTANDING NEW TAXANES MODIFIED IN C-2.-
UY29361A1 (en) PIRROLES AND IMIDAZOLS REPLACED, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE
BR112012008504A2 (en) composition for delivery of entrapped carbohydrate active agent and articles using the same
CL2015001640A1 (en) Saturated n-acetylated and nitrogen heterocycles that enhance the activity of an active antibiotic against mycobacteria
CL2015002817A1 (en) Formulation of amorphous calcium l-5-methyltetrahydrofolate (l-5-mthf-ca).
CR20110190A (en) SYNERGIC RODENTICIATED AGENT